Gastrointestinal colonization by OXA-48-producing Enterobacterales: risk factors for persistent carriage

• Published in: European journal of clinical microbiology & infectious diseases 2022-12, Vol.41 (12), p.1399-1405
• Main Authors: Lima, O., Sousa, A., Filgueira, A., González-Novoa, M. Carmen, Domínguez-López, Celina, Ávila-Nuñez, M., Represa, M., Rubiñán, P., Martínez-Lamas, L., Pérez-Castro, Sonia, Rubianes, M., Pérez-Rodríguez, M. T.
• Format: Article
• Language: English
• Subjects: Antibiotics; Antiinfectives and antibacterials; Biomedical and Life Sciences; Biomedicine; Ceftazidime; Colonization; Comorbidity; Decolonization; Digestive system; Enterobacterales; Epidemiology; Gastrointestinal tract; Internal Medicine; Medical Microbiology; Microorganisms; Observational studies; Original Article; Patients; Rectum; Risk analysis; Risk factors
• ISSN: 0934-9723; 1435-4373
• DOI: 10.1007/s10096-022-04504-6

Carbapenem-resistant Enterobacterales (CRE) infections are a major health problem. Intestinal colonization is a key factor in developing infection. However, factors associated with persistent colonization by CRE are unknown. The aim of the study was to identify factors associated with persistent CRE gut colonization. This is a retrospective, single-centre, observational study of adult patients with CRE gut colonization between January 2015 and January 2020. Epidemiologic characteristics, comorbidities, infectious events, duration of hospitalization and antimicrobial treatment received in the follow-up period were collected. Colonization was defined as isolation in at least 2 rectal swab culture samples of CRE. Decolonization was defined as 3 negative rectal swab cultures or 2 negative cultures and a negative molecular test. A cohort of 86 patients with CRE gut colonization was selected: 44 patients with spontaneous decolonization (DC) and 42 patients with persistent colonization (PC). The mean follow-up period was 24 months (IQR 14–33) in the DC group vs. 25 months (IQR 16–36) in the PC group ( p  = 0.478). Patient characteristics were similar between both groups. Colonization by other MDR microorganisms was high (44 patients, 51%) and slightly more common in the PC group (PC 60% vs. DC 43%, p  = 0.139). The use of ceftazidime-avibactam was more common among the PC group (PC 33% vs. DC 14%, p  = 0.041). We observed a higher percentage of antimicrobial therapy in the previous 30 days (PC 68% vs. DC 57%, p  = 0.371) and 90 days (PC 81% vs. DC 82%, p  = 0.353) in the PC group. Multivariable analysis showed that patients that have received ceftazidime-avibactam therapy (OR 4.9 95% CI [1.45–16.39], p  = 0.010), and those colonized by other MDR microorganisms (OR 2.5, 95% CI [0.96–6.25], p  = 0.060) presented a higher risk of PC. Ceftazidime-avibactam use and colonization by other MDR microorganisms might be associated with CRE persistent gut colonization.